You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
58 search results for: symposium
expert video
The Benefits of Early Intervention in AD: More Than Skin Deep – Q&A Session and Conclusion
Dermatology
This video from the March 2024 ADVENT AD symposium features the final panel discussion and conclusion. Dr. Eric Simpson, Dr. Katrina Abuabara and Dr. Lawrence Eichenfield discuss topics related to early intervention in AD and the impact of the cumulative disease burden that may manifest as atopic or non-atopic, systemic comorbidities. The faculty also field several questions submitted by the audience. Dr. Simpson concludes the panel discussion with a brief overview of the symposium.
Long-term Impacts of AD and the Potential Benefit of Early Intervention
Dermatology
In this highlight video from the March 2024 AD symposium, Dr. Lawrence Eichenfield discusses the potential importance of early intervention in pediatric patients, and how addressing AD at an early stage may stop the clock on associated systemic comorbidities in the long term.
Inflamm-aging: Systemic Inflammation and Frailty in Older Adults
Dermatology
In this highlight video from the March 2024 AD symposium, Dr. Katrina Abuabara discusses the concept of inflamm-aging in older adult patients. She explains how the term is defined through measures of systemic inflammatory markers and how immunosenescence can contribute to systemic comorbidities in older adults with AD.
Is Pediatric AD Linked to Other Allergic Diseases?
Dermatology
In this highlight video from the March 2024 AD symposium, Dr. Lawrence Eichenfield discusses the relationship between skin barrier dysfunction and the potential for increased risk of allergic sensitization. He goes on to discuss the high proportion of pediatric patients with AD who exhibit at least 1 atopic comorbidity.
Differential Diagnosis and Disease Onset in Older Adult Patients With AD
Dermatology
In this highlight video from the March 2024 AD symposium, Dr. Katrina Abuabara discusses disease onset in AD and how the condition may present at any age. She explains that late-onset AD in older adult populations tends to have more severe and more active disease compared to children and adults.
The Cumulative Disease Burden of AD in Adult Patients
Dermatology
In this highlight video from the March 2024 AD symposium, Dr. Eric Simpson discusses the array of allergic and non-allergic comorbidities that may impact adult patients with AD and how the cumulative burden of these comorbidities contributes to reduced quality of life. He goes on to discuss the potential for addressing the multimorbidities related to AD through early intervention before they have the opportunity to develop or progress.
What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP
Dermatology
This full video presentation of the March 2025 ADVENT cross-dermatology symposium, hosted in Orlando, Florida features Dr. Eric Simpson, Dr. Shawn Kwatra, Dr. Jason Hawkes and Dr. Victoria Werth. The faculty present the latest information around type 2 inflammation and its association with atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP).
The Benefits of Early Intervention in AD: More Than Skin Deep
Dermatology
This video presentation of the full March 2024 ADVENT Atopic Dermatitis (AD) symposium, hosted in San Diego, California, features Dr. Eric Simpson, Dr. Katrina Abuabara, and Dr. Lawrence Eichenfield. The faculty present the latest information around the inflammatory processes in AD that promote a wide range of systemic and local effects, emphasizing the impact they have on patients’ quality of life. The faculty also discuss how these processes and burdens vary at specific life stages and may accumulate over time if left unchecked.
Role of Type 2 Inflammation in Skin Barrier Disruption and Itch
Dermatology
In this highlight video from the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Christine Bangert discusses how type 2 inflammation contributes to epidermal barrier dysfunction and chronic itch in AD
Atopic Dermatitis as a Risk Factor for the Development of Food Allergies
Dermatology
In this video from the 2024 Society for Pediatric Dermatology Symposium held in Toronto, Canada, Dr. Peter Leo, MD discusses the role of atopic dermatitis as a risk factor for developing food allergies.
In this highlight video from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, Dr. Eric Simpson explores potential considerations when discussing the concept of disease modification and how early intervention might be disease modifying in AD.
In this highlight video from the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Christine Bangert describes how AD can persist into adulthood in many children with moderate-to-severe AD and discusses the risk factors for such persistence.
ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
For healthcare professionals in Algeria: Please read the additional Terms of Use.
All rights reserved. MAT-US-2305040 v3.0-P Exp. Date: 11/24/2025
All Rights Reserved.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.